492 related articles for article (PubMed ID: 16456688)
61. Bisphosphonates, phossy jaw, and bisphosphonate-related osteonecrosis of the jaw.
Lewis DM
J Okla Dent Assoc; 2011; 102(5):36-9. PubMed ID: 21874699
[No Abstract] [Full Text] [Related]
62. Uncovering the cause of "phossy jaw" Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed.
Marx RE
J Oral Maxillofac Surg; 2008 Nov; 66(11):2356-63. PubMed ID: 18940506
[TBL] [Abstract][Full Text] [Related]
63. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Carmagnola D; Celestino S; Abati S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
[TBL] [Abstract][Full Text] [Related]
64. Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case.
Shirota T; Nakamura A; Matsui Y; Hatori M; Nakamura M; Shintani S
Clin Oral Implants Res; 2009 Dec; 20(12):1402-8. PubMed ID: 19793318
[TBL] [Abstract][Full Text] [Related]
65. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
66. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.
Tirelli G; Biasotto M; Chiandussi S; Dore F; De Nardi E; Di Lenarda R
Head Neck; 2009 Sep; 31(9):1249-54. PubMed ID: 19260132
[TBL] [Abstract][Full Text] [Related]
67. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
Junquera L; Gallego L; Cuesta P; Pelaz A; de Vicente JC
Am J Otolaryngol; 2009; 30(6):390-5. PubMed ID: 19880027
[TBL] [Abstract][Full Text] [Related]
68. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
69. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
70. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Brooks JK; Gilson AJ; Sindler AJ; Ashman SG; Schwartz KG; Nikitakis NG
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):780-6. PubMed ID: 17223592
[TBL] [Abstract][Full Text] [Related]
71. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
[TBL] [Abstract][Full Text] [Related]
72. [Relationship between osteonecrosis of the jaw and bisphosphonate treatment].
Badel T; Keros J; Krapac L; Pavicin IS
Arh Hig Rada Toksikol; 2010 Sep; 61(3):371-80. PubMed ID: 20860977
[TBL] [Abstract][Full Text] [Related]
73. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Otto S; Pautke C
J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
[TBL] [Abstract][Full Text] [Related]
74. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
75. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Dannemann C; Grätz KW; Riener MO; Zwahlen RA
Bone; 2007 Apr; 40(4):828-34. PubMed ID: 17236837
[TBL] [Abstract][Full Text] [Related]
76. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N
J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045
[TBL] [Abstract][Full Text] [Related]
77. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
[TBL] [Abstract][Full Text] [Related]
78. Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Statz TA; Guthmiller JM; Humbert LA; Johnson GK
J Periodontol; 2007 Nov; 78(11):2203-8. PubMed ID: 17970689
[TBL] [Abstract][Full Text] [Related]
79. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
Friedrich RE; Blake FA
Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
[TBL] [Abstract][Full Text] [Related]
80. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
